State of the neoadjuvant therapy for glioblastoma multiforme—Where do we stand?
Naeim Nabian, Reza Ghalehtaki, Mehdi Zeinalizadeh, Carmen Balañá, Paola Anna Jablonska
Abstract
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Despite several investigations in this field, maximal safe resection followed by chemoradiotherapy and adjuvant temozolomide with or without tumor-treating fields remains the standard of care with poor survival outcomes. Many endeavors have failed to make a dramatic change in the outcomes of GBM patients. This study aimed to review the available strategies for newly diagnosed GBM in the neoadjuvant setting, which have been mainly neglected in contrast to other solid tumors.
Topics & Concepts
TemozolomideMedicineGlioblastomaOncologyNeoadjuvant therapyChemoradiotherapyInternal medicineAdjuvantAdjuvant therapyRadiation therapyChemotherapyOverall survivalCancerCancer researchBreast cancerGlioma Diagnosis and TreatmentRadiomics and Machine Learning in Medical ImagingBrain Metastases and Treatment